Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
Revenue
Fusion Antibodies PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fusion Antibodies PLC
LSE:FAB
|
Revenue
£1.6m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Revenue
£169.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Revenue
£48.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Diaceutics PLC
LSE:DXRX
|
Revenue
£19.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Ergomed PLC
LSE:ERGO
|
Revenue
£152.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
hVIVO PLC
LSE:HVO
|
Revenue
£57.8m
|
CAGR 3-Years
77%
|
CAGR 5-Years
32%
|
CAGR 10-Years
36%
|
See Also
What is Fusion Antibodies PLC's Revenue?
Revenue
1.6m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Revenue amounts to 1.6m GBP.
What is Fusion Antibodies PLC's Revenue growth rate?
Revenue CAGR 5Y
-4%
Over the last year, the Revenue growth was -63%. The average annual Revenue growth rates for Fusion Antibodies PLC have been -27% over the past three years , -4% over the past five years .